Mahavir Singh

Mahavir Singh

Mahavir Singh

Owner of LIONEX


Founding Director, LIONEX Diagnostics & Therapeutics GmbH, Braunschweig, Germany

Head of the group and permanent Staff member (Senior Scientist): Helmholtz Zentrum für Infektionsforschung GmbH (till Sept.2015)

Affiliated Professor of Genetics, Technical University of Braunschweig, Germany


Drug targets and drug development for TB.

TB-Diagnosis and Vaccine development; Mucosal vaccines against HIV and TB;

Molecular genetics of Mycobacterium tuberculosis; Diagnosis of Bovine Tuberculosis; Molecular biotechnology; Oxidative stress in Mycobacteria and Trypanosomes;

Heat shock proteins and their role in diseases;

More than 160 publications in international peer-review journals

Supervised 10 doctoral and 20 Diploma students

Grant Acquisitions: Principal Investigator and Coordinator of a number of research projects funded by the European Union, Gates Foundation, WHO, German Ministry of Science and Technology.


Novel, low-cost tuberculosis tests

A. A. Elamin1, D. Martens2,3, A. B. González-Guerrero4, M. Stehr1, F. Jonas1, W. Van Roy5, R. Vos5, A. Stassen5, S. Severi5, R. Bockstaele6, P. Soetaert6, B. Anton7, H. Becker7, L. M. Lechuga4, P. Bienstman2,3, M. Singh1

1LIONEX GmbH, Salzdahlumer Str. 196, Building 1A, 38126 Braunschweig, Germany

2Photonics Research Group, Ghent University-IMEC, Technologiepark-Zwijnaarde 15, 9052 Ghent, Belgium

3Center for Nano-and Biophotonics, Ghent University, Technologiepark-Zwijnaarde 15, 9052 Ghent, Belgium

4 Nanobiosensors and Bioanalytical Applications Group, Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and The Barcelona Institute of Science and Technology, 08193 Barcelona, Spain

5IMEC, Kapeldreef 75, 3001 Leuven, Belgium

6Trinean NV, Dulle Grietlaan 17/3 9050 Gentbrugge, Belgium

7microfluidic ChipShop GmbH, Stockholmer Str. 20, 07747 Jena, Germany

Tuberculosis (TB) is an old but re-emerging global health threat caused by the Mycobacterium tuberculosis (Mtb). Despite the greatest global health impact of TB, case detection rates are low, posing serious hurdles for TB control. Current methods for the detection of TB are either time consuming or require expensive instruments. Therefore, accurate, novel, rapid, more sensitive and cost effective diagnostics are urgently needed.

In this respect, the goal of the European FP7 Pocket project is to establish a framework to combine several state-of-the-art concepts for the development of a novel and cost-effective point-of-care test for tuberculosis using patients samples. The new tuberculosis POCT consists of a small photonic chip combined with a microfluidic cartridge (disposable part) and a graphical user interface instrument, used for optical readout and data processin. An integrated label-free photonic circuit is used as biosensor, a low-cost mechanism due to its small size and the compatibility with mature CMOS fabrication technology. The successful development of a POCT TB test depends on an Mtb-specific biomarker. Novel, high-quality and selective antibodies were developed by LIONEX. A unique cocktail of Biomarkers promises to significantly enhance the sensitivity and specificity far beyond current TB tests. Initial results indicate the successful detection of 250 pg/ml of a biomarker in urine, thus demonstrating its potential for use in resource-limited area and for the on-line diagnosis of TB. In the new POCT, the safety of sample process has been successfully implemented using microfluidic chip as transfer medium. The designed chip has very low fabrication costs, allowing cost-effective disposable chips to be fabricated in mass production.

This highly promising TB POCT shall be evaluated in order to determine a universal threshold, especially in endemic countries as well as its performance in the field.

Acknowledgement: The Pocket project was funded by the European Commission under grant agreement no FP7 610389.

Read more about Mahavir and his work here.